The role of DAB2IP in androgen receptor activation during prostate cancer progression (Q39162930)

9 September 2017

The role of DAB2IP in androgen receptor activation during prostate cancer progression (English)

1 reference

9 September 2017

1 reference

K Wu

1

1 reference

9 September 2017

J Liu

2

1 reference

9 September 2017

S-F Tseng

3

1 reference

9 September 2017

C Gore

4

1 reference

9 September 2017

Z Ning

5

1 reference

9 September 2017

N Sharifi

6

1 reference

9 September 2017

L Fazli

7

1 reference

9 September 2017

M Gleave

8

1 reference

9 September 2017

P Kapur

9

1 reference

9 September 2017

G Xiao

10

1 reference

9 September 2017

X Sun

11

1 reference

9 September 2017

O K Oz

12

1 reference

9 September 2017

W Min

13

1 reference

9 September 2017

G Alexandrakis

14

1 reference

9 September 2017

C-R Yang

15

1 reference

9 September 2017

C-L Hsieh

16

1 reference

9 September 2017

H-C Wu

17

1 reference

9 September 2017

D He

18

1 reference

9 September 2017

D Xie

19

1 reference

9 September 2017

J-T Hsieh

20

1 reference

9 September 2017

language of work or name

English

0 references

publication date

22 April 2013

1 reference

9 September 2017

1 reference

9 September 2017

33

1 reference

9 September 2017

1954-1963

1 reference

9 September 2017

15

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.143

9 September 2017

0 references

cites work

Androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Nuclear receptor coregulators: cellular and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

The role of androgen receptor mutations in prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Formation of the androgen receptor transcription complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

SH2 and SH3 domains as targets for anti-proliferative agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Invasive prostate carcinoma driven by c-Src and androgen receptor synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.143

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.143

1 reference

Dimensions Publication ID

9 September 2017

0 references

1 reference